Clover Health Investments Stock (NASDAQ: CLOV)

Dernières nouvelles pour Clover Health Investments (NASDAQ:CLOV) Stock

Clover Health Investments

Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Clover Health Investments, Corp. - Class A Common stock

Clover Health Investments Corp

CLOVER CORP LTD by Clover Corporation Ltd.

CLOVER LEAF CAP CORP RT

Clover Finance - United States Dollar

Clover Leaf Capital Corp

Clover Leaf Capital Corp Units (1 Ord Share Class A & 1 Right)

CLOVERLEAF KENNEL CLB A by Cloverleaf Kennel Club

Cloverleaf Kennel Club

Clovis Oncology Inc

Telsey Advisory Group analyst Dana Telsey maintains Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) with a Market Perform and maintains $62 price target.

News

Price Target

Analyst Ratings

Telsey Advisory Group Maintains Market Perform on Signet Jewelers, Maintains $62 Price Target

Student loan debt in the United States has reached unprecedented levels, with borrowers collectively owing more than $1.77 trillion as of 2025, according to the Education Data Initiative.&nbsp;
As tuition costs continue to rise, many graduates struggle to manage monthly payments which can lead to challenges including delinquency, default and<a href="https://www.benzinga.com/personal-finance/management/25/06/45739976/trump-administration-pauses-social-security-garnishments-over-defaulted-student-loans-department-will-begin-proactive-outreach-to-recipients"> long-term financial insecurity.&nbsp;</a>
One TikTok-er has a "solution."&nbsp;
Read Next: <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june?utm_source=articleShare">Space Stocks Weekly Countdown: RocketLab Gets Analyst Love While Virgin Galactic Slides Into June</a>
The Details: TikTok user @thenormajeane5 recently went viral with <a href="https://www.tiktok.com/@thenormajeane5/video/7509221877844446510?lang=en">a post</a> detailing his unconventional strategy: staying in school indefinitely to keep student loans in deferment and avoid repayment.&nbsp;
<figure class="wp-block-embed is-type-video is-provider-tiktok wp-block-embed-tiktok"> 
<div class="wp-block-embed__wrapper">
<blockquote class="tiktok-embed" cite="https://www.tiktok.com/@thenormajeane5/video/7509221877844446510" data-video-id="7509221877844446510" data-embed-from="oembed" style="max-width:605px; min-width:325px;"> <section> <a target="_blank" title="@thenormajeane5" href="https://www.tiktok.com/@thenormajeane5?refer=embed">@thenormajeane5</a>
For legal purporses this is SATIRE: I'm never going to pay back those student loans. &#8211; don't get me wrong I know it's inevitable and I hope to be in a better place in the future I guess. 
 <a target="_blank" title="♬ Don't Forget About Us - KAYTRANADA Remix - Mariah Carey &#038; KAYTRANADA" href="https://www.tiktok.com/music/Don't-Forget-About-Us-KAYTRANADA-Remix-7489248146356586512?refer=embed">♬ Don&#8217;t Forget About Us &#8211; KAYTRANADA Remix &#8211; Mariah Carey &#038; KAYTRANADA</a> </section> </blockquote>
<script async src="https://www.tiktok.com/embed.js"></script></div>
</figure>
Thenormajeane5, who is currently working toward a doctoral degree, explained that after graduating in about two and a half years, he plans to keep pursuing associate degrees for the rest of his life in order to remain a lifelong student and postpone repayment indefinitely.&nbsp;
The creative approach resonated with thousands online, racking up nearly 500,000 likes and more than 11,000&nbsp; comments.&nbsp;
Many viewers shared similar stories. One commenter said their professor had over $800,000 in student loans and was still enrolled, joking that he'd never pay it back. Another mentioned their grandmother, who kept enrolling in new degrees and was about to graduate with her master's degree.&nbsp;
Others described using employer tuition reimbursement programs to keep taking classes, or simply repeating the deferment strategy for years.&nbsp;
Read Next: <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45727360/amazon-analyst-sees-robotics-unlocking-billions-in-savings?utm_source=articleShare">Amazon Analyst Sees Robotics Unlocking Billions In Savings</a>
Other Options: Student loan borrowers have other, perhaps more financially responsible options, including income-driven repayment plans and student loan refinancing.&nbsp;
Borrowers struggling to repay federal student loans can apply for an <a href="https://studentaid.gov/manage-loans/repayment/plans/income-driven#:~:text=An%20income%2Ddriven,0%20per%20month.">income-driven repayment</a> plan which bases monthly student loan payment amounts on income and family size. For some people, payments on an IDR plan can be as low as $0 per month.
Borrowers with private student loans have other options like refinancing in order to achieve lower monthly payments. SoFi Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) specializes in student loan refinancing and Citizens Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) offers student loan refinancing through Citizens Bank.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/management/25/05/45675714/can-michael-burrys-nvidia-short-survive-the-stocks-stunning-comeback?utm_source=articleShare">Can Michael Burry&#8217;s Nvidia Short Survive The Stock&#8217;s Stunning Comeback?</a></li>
</ul>
Image: Shutterstock

Social Media

Personal Finance

General

SOFI

The Viral Student Loan Solution People Can't Stop Talking About

Stifel analyst Matthew Smith maintains The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Hold and lowers the price target from $40 to $38.

Stifel Maintains Hold on The Campbell's, Lowers Price Target to $38

Telsey Advisory Group analyst Cristina Fernandez maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Outperform and maintains $60 price target.

Telsey Advisory Group Maintains Outperform on Academy Sports, Maintains $60 Price Target

Stifel analyst Selman Akyol maintains Kinder Morgan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) with a Hold and raises the price target from $27 to $28.

Stifel Maintains Hold on Kinder Morgan, Raises Price Target to $28

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) may be setting up for a massive rally if its long-term logarithmic growth channel holds, according <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">to traders&#8217; analysis.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.1949</td>
<td>$29.2 billion</td>
<td>+2.7%&nbsp;</td>
<td>-14.9%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001315</td>
<td>$7.8 billion</td>
<td>+2.9%&nbsp;</td>
<td>-9.5%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001260</td>
<td>$5.3 billion</td>
<td>+8.9%&nbsp;</td>
<td>-10.2%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: On June 3, crypto analyst Kevin highlighted a key support zone between $0.1839 and $0.1901 as a launchpad for the next leg higher.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Come on <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> show us what your made of &#x1f91d; <a href="https://t.co/5omq3H4ppQ">https://t.co/5omq3H4ppQ</a> <a href="https://t.co/ndgJ7Ms1vc">pic.twitter.com/ndgJ7Ms1vc</a>
&mdash; Kevin (@Kev_Capital_TA) <a href="https://twitter.com/Kev_Capital_TA/status/1929711717069758638?ref_src=twsrc%5Etfw">June 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto Tony <a href="https://x.com/CryptoTony__/status/1929863383601332651">remains</a> long from $0.148, expecting a breakout above $0.248 to confirm the next move. 
Trader Tardigrade pointed to Dogecoin's 3-day RSI hovering around 50, a level that has historically preceded major rallies, with upside potential toward $1.
Meanwhile, Bitcoinsensus <a href="https://x.com/Bitcoinsensus/status/1929469386957713620">identified</a> that DOGE has been respecting a logarithmic channel since 2014. 
Past performances include: a 10x from 2014 to 2017 and a 37x from 2017 to 2021. 
This could lead to a possible 21x from 2021 to a projected 2025 peak.
If this pattern plays out, DOGE could reach up to $16, an extraordinary gain backed by a decade of price action rather than just short-term hype.
Statistics: On May 31, Whale Alert <a href="https://x.com/whale_alert/status/1928867003378397425">reported</a> a 104.13 million DOGE transfer, worth around $20 million, to Coinbase on May 31, sparking some concerns over potential sell pressure.
Coinglass data shows Dogecoin liquidations in the past 24 hours at $3.6 million, with $2.39 million in short liquidations. Open interest in a single day spiked 3.2% while DOGE derivatives trading volume expanded by 12.4%. Options volume is up by 185%.
Community News: On June 1, Dogecoin Foundation's senior software engineer Ed Tubbs <a href="https://x.com/EdTubbs/status/1929236466166558746">announced</a> the release of libdogecoin v0.1.4, which introduces Trusted Execution Environment (TEE) for secure key management and signatures.
With this upgrade, Dogecoin becomes one of the first cryptocurrencies to support TEE, a feature designed to enhance wallet security in the face of rising threats across the crypto ecosystem.
Currently, DOGE boasts $1.06 billion in trading volume, reflecting growing market interest.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45624852/dogecoins-chart-screams-caution-as-bulls-get-rejected-again">Dogecoin&#8217;s Chart Screams Caution As Bulls Get Rejected Again</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Could Explode For A 2,100% Gain If This Pattern Holds, Trader Warns

Effective June 2, 2025, Ernexa Therapeutics Inc. (the &quot;Company&quot;), filed a certificate of amendment to the Company&#39;s Restated Certificate of Incorporation, as amended (the &quot;Amended COI&quot;) with the Secretary of State of Delaware to increase the authorized shares of its common stock from 100,000,000 to 150,000,000.
&nbsp;
Additionally, effectively June 2, 2025, the Company filed a certificate of amendment to its Amended COI with the Secretary of State of Delaware to allow for action required or permitted to be taken by stockholders of the Company to be effected by written consent of such stockholders in addition to duly called annual or special meetings of such stockholders.

ERNA

Reported June 2, 2025: Ernexa Therapeutics Amends Certificate Of Incorporation To Increase Authorized Common Stock From 100M To 150M Shares

New long-term CARTITUDE-1 data show one-third of patients treated with CARVYKTI&#xAE;&nbsp;remain progression-free
CARTITUDE-4 analysis shows compelling overall survival and progression-free benefits in standard and high-risk subgroups across prior lines of treatment
CHICAGO, June 3, 2025 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today new long-term follow-up data from the Phase 1b/2 CARTITUDE-1 study demonstrating 33 percent (n=32) of patients in the study (n=97) with relapsed or refractory multiple myeloma (RRMM) treated with CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) achieved progression-free survival (PFS) of five years or more with a single infusion and no maintenance or subsequent anti-myeloma therapy.1 These data underscore Johnson &amp; Johnson's dedication to advancing transformative therapies that aim to reshape the treatment landscape for patients with multiple myeloma.
In a subset of 12 patients who underwent serial evaluations at a single site, all were minimal residual disease (MRD) negative and imaging negative throughout five years of post-treatment follow-up. Findings were featured in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #7507). The data were also simultaneously published in The Journal of Clinical Oncology.

Johnson & Johnson Says New Long-Term CARTITUDE-1 Data Show One-Third Of Patients Treated With CARVYKTI Remain Progression-Free

Stifel analyst Tore Svanberg maintains Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) with a Buy and raises the price target from $69 to $80.

CRDO

Stifel Maintains Buy on Credo Technology Group, Raises Price Target to $80

Telsey Advisory Group analyst Dana Telsey maintains Designer Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBI#NYSE">DBI</a>) with a Market Perform and maintains $5 price target.

Telsey Advisory Group Maintains Market Perform on Designer Brands, Maintains $5 Price Target

More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO&#xAE;&nbsp;for 24 months or longer in the Phase 3 PERSEUS study
Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO&#xAE; in transplant-ineligible newly diagnosed patients
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced data from two studies highlighting that a DARZALEX FASPRO&#xAE; (daratumumab and hyaluronidase-fihj)-based quadruplet regimen demonstrated deep and sustained minimal residual disease (MRD) negativity rates, and improved long-term progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM), regardless of transplant status.1,2,3 Findings were highlighted as oral presentations of an analysis of sustained MRD in transplant-eligible patients from the Phase 3 PERSEUS study (Abstract #7501) and a subgroup analysis of transplant-ineligible patients in the Phase 3 CEPHEUS study (Abstract #7516) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Johnson & Johnson Announces Data From Two Studies Highlighting That DARZALEX FASPRO-Based Quadruplet Regimen Demonstrated Deep And Sustained MRD Negativity Rates, And Improved Long-Term PFS In NDMM Patients

Rumors

Trading Ideas

CURI

Watching CuriosityStream; Traders Circulate Zacks Under $10 Newsletter Picks Stock

VUZI

Wyr.ai Partners With Vuzix On Launch Of M400 Smart Glasses-Based AI Quality Assurance Inspection Platform; Terms Not Disclosed

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) with a Buy and maintains $16 price target.

ESLA

D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target

Phase 1 trial demonstrates encouraging clinical activity of investigational&nbsp;immunotherapy for relapsed or refractory multiple myeloma
Novel investigational dual-antigen-targeting&nbsp;immunotherapy binds to B-cell maturation antigen (BCMA) and GPRC5D on myeloma cells, as well as CD3 on T-cells&nbsp;
CHICAGO, June 3, 2025 /PRNewswire/ -- Johnson &amp; Johnson announced today initial Phase 1 results of JNJ-79635322 (JNJ-5322), a novel investigational trispecific antibody (TsAb) in patients with relapsed or refractory multiple myeloma. Among the 36 patients who received the recommended phase 2 dose (RP2D), the overall response rate (ORR) was 86.1 percent. In the 27 patients who were naive to BCMA and GPRC5D directed therapies, the ORR was 100 percent at the RP2D. Findings were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=1437573614&amp;u=https%3A%2F%2Fmeetings.asco.org%2Fmeetings%2F2025-asco-annual-%2520meeting%2F327%2Fprogram-guide%2Fscheduled-sessions&amp;a=2025+American+Society+of+Clinical+Oncology+(ASCO)+Annual+Meeting">2025 American Society of Clinical Oncology (ASCO) Annual Meeting</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2239716214&amp;u=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2FABSTRACT489908&amp;a=7505">7505</a>). The study will also be featured as one of the six best abstracts during the Plenary Abstracts Session at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=2405979170&amp;u=https%3A%2F%2Fehaweb.org%2Fcongress%2Feha2025-congress%2F&amp;a=2025+European+Hematology+Association+(EHA)+Congress">2025 European Hematology Association (EHA) Congress</a> (Abstract #<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439656-1&amp;h=3428041764&amp;u=https%3A%2F%2Flibrary.ehaweb.org%2Feha%2F2025%2Feha2025-congress%2F4159177%2Frakesh.popat.first-in-human.study.of.jnj-79635322.28jnj-532229.a.novel.html%3Ff%3Dmenu%253D6%252Abrowseby%253D8%252Asortby%253D2%252Amedia%253D3%252Ace_id%253D2882%252Amarker%253D5848%252Afeatured%253D19595&amp;a=S100">S100</a>).

Johnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma

WIIM

ENTA

Enanta Pharmaceuticals shares are trading higher after JMP Securities maintained an Outperform rating on the stock and raised its price target from $23 to $24.

A 22-year-old college student called into &#8220;<a href="https://www.youtube.com/watch?v=3Sg4BQWIYyo">The Ramsey Show</a>&#8221; and said he was being financially &#8220;abused&#8221; by his parents. The student, identified only as Tyler, said he had been following Dave Ramsey&#8216;s <a href="http://www.benzinga.com/personal-finance/25/05/45680116/couple-making-200k-wants-to-invest-60-of-their-income-dave-ramsey-says-thats-great-but-build-up-a-fat-juicy-down-payment-for-a-house-instead">baby steps</a> and recently used a school refund to pay off debt. His parents were not happy about it.
<h2 class="wp-block-heading">Student Loan Refund Sparks Family Drama</h2>
&#8220;I got my refund from school in May and it was close to about $4,000—exactly $3,999,&#8221; Tyler told hosts Jade Warshaw and Ken Coleman. &#8220;I used that money to pay off my debt, my car payment, and a little bit of my credit card payment.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
</ul>
Tyler said his parents were furious, claiming the money was theirs. &#8220;They were just absolutely furious about me, saying that that was their money and about the hard work they did to put me out here,&#8221; he explained.
He summed up the situation in one sentence: &#8220;My parents are financially abusing me.&#8221;
Coleman asked for clarification: was the refund from money Tyler had earned through work, or was it part of a student loan? Tyler said it was a mix of both—federal work-study and student loan overage.
When asked whose name was on the loan, Tyler replied, &#8220;I believe it&#8217;s mom and then me. I believe I&#8217;m the co-signer on it.&#8221;
That raised a red flag for the hosts. &#8220;You should have communicated with the parents because they&#8217;re involved in this financially,&#8221; Coleman told him..
Warshaw agreed, saying that while <a href="https://www.benzinga.com/money/how-to-pay-off-debt">paying off debt</a> was a smart instinct, Tyler should have talked to his mom first. &#8220;If your mom was like, &#8216;Wait a minute, you took this loan money that we&#8217;re both on the hook for to do this thing without consulting both of us,&#8217; I can see that,&#8221; she said.
Trending: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Is It Really Abuse?</h2>
Tyler accused his parents of financially abusing him, but both hosts pushed back on the use of that word.
&#8220;I see no evidence of that,&#8221; Warshaw said bluntly. &#8220;You&#8217;re 22 now. Your parents can make suggestions, they can even try to strong-arm you to do things their way, but you don&#8217;t have to.&#8221;
Coleman was more direct: &#8220;You need to stop saying they&#8217;re financially abusing you because this is not anywhere close to it. It&#8217;s dramatic, and by the way, words matter.&#8221;
Tyler claimed the tension comes from his parents&#8217; spending habits. &#8220;They&#8217;re both spenders&#8230; My mom just bought a brand new Mercedes. My dad spends money constantly on his new truck,&#8221; he said. &#8220;They&#8217;ve always been haggling me for money.&#8221;
He also said they pressured him to help pay for a down payment on a truck—something he didn't want to do. Warshaw responded, &#8220;Then you don&#8217;t have to do it.&#8221;
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
<h2 class="wp-block-heading">Future Debt Could Tie Him To Parents Even More</h2>
The conversation shifted toward Tyler&#8217;s financial future. He currently has $40,000 in student loans and expects it to reach around $80,000 after finishing his degree in sports management at the University of Tennessee.
&#8220;You&#8217;re following in [your parents&#8217;] footsteps right now because you are taking on debt and you&#8217;re <a href="https://www.benzinga.com/personal-finance/24/11/41914082/dave-ramsey-says-its-stupid-to-go-into-debt-for-a-career-you-dont-borrow-money-to-cross-state-lines">going to an out-of-state school</a>,&#8221; Warshaw said. She advised Tyler to consider in-state options or work his way through school without borrowing more money, especially since his mother is on the loans.
&#8220;Mama&#8217;s going to be breathing down your neck every month, talking about, &#8216;Where&#8217;s the payment? You&#8217;re messing up my credit,'&#8221; she warned. &#8220;And that is going to jack you and her.&#8221;
Coleman added, &#8220;Nobody cares where you get your degree from. There&#8217;s a better way, Tyler.&#8221;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
Image: Shutterstock

'My Parents Are Financially Abusing Me'—A College Kid Used His $3,999 School Refund To Pay Off Debt, But His Parents Say It Belongs To Them

Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), the world's largest corporate holder of Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) on Monday introduced a new preferred stock product: Series A Stride Preferred (STRD) is designed to provide a <a href="https://www.benzinga.com/crypto/25/06/45718471/michael-saylors-strategy-outperforms-apple-tesla-amazon-and-other-mag-7-stocks-and-its-not-even-close-has-the-bitcoin-treasury-bet-paid-off">high-yield return for long-term investors.</a>
The STRD <a href="https://x.com/saylor/status/1929871463521136697">offering</a> marks the company's third preferred instrument as it continues building a structured and diversified capital stack anchored in Bitcoin exposure.
STRD delivers a fixed 10% dividend with perpetual duration and ranks below Strategy's senior preferred instrument (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), but above the firm's common equity.
It is structured to sit at the riskier end of the firm's yield curve but compensates investors with its highest payout to date among Strategy's preferred options.
Unlike (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRF#NASDAQ">STRF</a>), which prioritizes capital preservation and mimics the risk profile of investment-grade fixed income, STRD is intended for investors seeking higher returns despite increased subordination.
Meanwhile, Strategy's other product STRK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRK#NASDAQ">STRK</a>) offers an 8% dividend and the added benefit of convertibility, placing it squarely between STRF and STRD in terms of both yield and risk.
Strategy's common stock MSTR remains the base layer of its capital stack, functioning as the firm's core vehicle for leveraged Bitcoin exposure.
The STRD issuance is non-callable in typical market conditions, though it may be repurchased if certain events occur, such as a major corporate restructuring or tax-related change. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45744569/michael-saylors-strategy-to-outperform-bitcoin-heres-how-it-could-happen">Michael Saylor&#8217;s Strategy To Outperform Bitcoin? Here&#8217;s How It Could Happen</a>
Dividends will be distributed quarterly, in cash, but only at the discretion of the board.
The firm claims STRD compares favorably to other high-yield investment vehicles on the market. 
For example, unlike ETFs such as iShares Preferred &amp; Income Securities ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFF#NASDAQ">PFF</a>) and iShares Broad USD High Yield Corporate Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USHY#NASDAQ">USHY</a>), STRD carries no management fees and offers a stronger yield proposition: 10% versus 7–8% for its ETF counterparts, while maintaining comparable volatility.
This new product aligns with Strategy's broader push to merge structured financial instruments with crypto exposure. 
The goal: deliver yield, diversification and exposure to digital assets in formats that fit traditional investment portfolios.
According to the company, the launch of STRD further extends its commitment to modernizing capital formation strategies using a layered and yield-tiered approach rooted in both crypto conviction and financial discipline.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/06/45741645/ethereum-books-record-institutional-inflows-xrp-sees-outflows-what-is-going-on">Ethereum Books Record Institutional Inflows, XRP Sees Outflows: What Is Going On?</a></li>
</ul>
Image: Shutterstock

$BTC

MSTR

iShares S&P US Preferred Stock Index Fund

STRF

STRK

USHY

Strategy Launches STRD Preferred Stock Offering 10% Yield

<ul>
<li>Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI&#xAE; with one-third of patients with relapsed/refractory multiple myeloma progression-free for ≥5 years</li>
<li>CARTITUDE-4 subgroup analyses featured in a poster presentation highlight consistent, durable progression-free and overall survival benefit vs. standard therapies across cytogenetic risk groups as early as second-line therapy</li>
<li>Promising early results from ongoing Phase 1 dose-escalation studies of LB1908 in gastroesophageal cancers and LB2102 in lung cancers underscore potential of next-generation cell therapies &nbsp;</li>
</ul>
SOMERSET, N.J., June 03, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) (Legend Biotech), a global leader in cell therapy, announced today new long-term results from the CARTITUDE-1 study in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. RRMM patients were treated with a single infusion of CARVYKTI&#xAE; (ciltacabtagene autoleucel; cilta-cel) with no maintenance or subsequent myeloma therapy. Notably, an unprecedented 33% (32 of 97) of patients remained progression-free for five years or more.
These data were featured in an oral presentation at the 2025&nbsp;American Society of Clinical Oncology&nbsp;(ASCO) Annual Meeting (<a href="https://www.globenewswire.com/Tracker?data=SUvaU_r4L_ZQGCtcGNJFmwrN7awYRxvTJx-N64piM7dYeIDzCpoh6j_mHdFQX52t67C83Czvmcia9-49Nw4jEJkkqeoBXxtLV3aq3F2REjHx5e2-DGfM4zrlCFa_8zyYtNWxf7rSBbYfxybbPj60vg==">Abstract #7505</a>). To date, more than 6,500 patients have been treated with CARVYKTI&#xAE;, the first and only CAR T-cell treatment in multiple myeloma to show overall survival benefit vs. standard of care.
In a subset of 12 patients from a single center from this analysis who underwent serial minimal residual disease (MRD) assessments, all 12 patients remained progression-free ≥5 years, were MRD-negative and showed no disease on annual PET/CT scans for five years.

LEGN

Legend Biotech Announces New Long-Term Results From CARTITUDE-1 Study In Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients

ALTG

Alta Equipment Group shares are trading higher after the company disclosed in a Form4 filing that the director, Andrew Studdert, accuired approximately 10,000 shares at an average price of $4.80 per share.

Comments

Clover Health Investments

Actualités

Dernières nouvelles pour Clover Health Investments (NASDAQ:CLOV) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL